• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无载体mRNA疫苗在小鼠和非人类灵长类动物中诱导出针对SARS-CoV-2的强大免疫力,且无全身反应原性。

Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity.

作者信息

Abbasi Saed, Matsui-Masai Miki, Yasui Fumihiko, Hayashi Akimasa, Tockary Theofilus A, Mochida Yuki, Akinaga Shiro, Kohara Michinori, Kataoka Kazunori, Uchida Satoshi

机构信息

Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki 210-0821, Japan.

Department of Research, NANO MRNA Co., Ltd., 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki 210-0821, Japan.

出版信息

Mol Ther. 2024 May 1;32(5):1266-1283. doi: 10.1016/j.ymthe.2024.03.022. Epub 2024 Apr 2.

DOI:10.1016/j.ymthe.2024.03.022
PMID:38569556
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11081875/
Abstract

Carrier-free naked mRNA vaccines may reduce the reactogenicity associated with delivery carriers; however, their effectiveness against infectious diseases has been suboptimal. To boost efficacy, we targeted the skin layer rich in antigen-presenting cells (APCs) and utilized a jet injector. The jet injection efficiently introduced naked mRNA into skin cells, including APCs in mice. Further analyses indicated that APCs, after taking up antigen mRNA in the skin, migrated to the lymph nodes (LNs) for antigen presentation. Additionally, the jet injection provoked localized lymphocyte infiltration in the skin, serving as a physical adjuvant for vaccination. Without a delivery carrier, our approach confined mRNA distribution to the injection site, preventing systemic mRNA leakage and associated systemic proinflammatory reactions. In mouse vaccination, the naked mRNA jet injection elicited robust antigen-specific antibody production over 6 months, along with germinal center formation in LNs and the induction of both CD4- and CD8-positive T cells. By targeting the SARS-CoV-2 spike protein, this approach provided protection against viral challenge. Furthermore, our approach generated neutralizing antibodies against SARS-CoV-2 in non-human primates at levels comparable to those observed in mice. In conclusion, our approach offers a safe and effective option for mRNA vaccines targeting infectious diseases.

摘要

无载体裸mRNA疫苗可能会降低与递送载体相关的反应原性;然而,它们对传染病的有效性一直不太理想。为了提高疗效,我们针对富含抗原呈递细胞(APC)的皮肤层,并使用了喷射注射器。喷射注射有效地将裸mRNA引入皮肤细胞,包括小鼠体内的APC。进一步分析表明,APC在皮肤中摄取抗原mRNA后,迁移至淋巴结(LN)进行抗原呈递。此外,喷射注射引发了皮肤局部淋巴细胞浸润,起到了疫苗接种的物理佐剂作用。在没有递送载体的情况下,我们的方法将mRNA分布限制在注射部位,防止全身mRNA泄漏及相关的全身促炎反应。在小鼠疫苗接种中,裸mRNA喷射注射在6个月内引发了强烈的抗原特异性抗体产生,同时在LN中形成生发中心,并诱导CD4和CD8阳性T细胞。通过靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白,这种方法提供了针对病毒攻击的保护。此外,我们的方法在非人类灵长类动物中产生了与在小鼠中观察到的水平相当的针对SARS-CoV-2的中和抗体。总之,我们的方法为针对传染病的mRNA疫苗提供了一种安全有效的选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d30/11081875/34900167294c/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d30/11081875/96fcd8797eaa/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d30/11081875/420aec20bc33/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d30/11081875/31c8d5cb7f79/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d30/11081875/7ace8e2b999a/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d30/11081875/2bdee730b47e/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d30/11081875/1bfeda2c7d02/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d30/11081875/34900167294c/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d30/11081875/96fcd8797eaa/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d30/11081875/420aec20bc33/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d30/11081875/31c8d5cb7f79/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d30/11081875/7ace8e2b999a/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d30/11081875/2bdee730b47e/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d30/11081875/1bfeda2c7d02/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d30/11081875/34900167294c/gr6.jpg

相似文献

1
Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity.无载体mRNA疫苗在小鼠和非人类灵长类动物中诱导出针对SARS-CoV-2的强大免疫力,且无全身反应原性。
Mol Ther. 2024 May 1;32(5):1266-1283. doi: 10.1016/j.ymthe.2024.03.022. Epub 2024 Apr 2.
2
Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.mRNA 疫苗对小鼠进行同侧或对侧增强免疫可提供针对 SARS-CoV-2 奥密克戎株的等效免疫和保护。
J Virol. 2024 Sep 17;98(9):e0057424. doi: 10.1128/jvi.00574-24. Epub 2024 Aug 28.
3
Delivery of Experimental mRNA Vaccine Encoding the RBD of SARS-CoV-2 by Jet Injection.经喷射注射传递编码 SARS-CoV-2 RBD 的实验性 mRNA 疫苗。
Bull Exp Biol Med. 2024 Apr;176(6):776-780. doi: 10.1007/s10517-024-06107-x. Epub 2024 Jun 19.
4
Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant.使用联合佐剂进行异源肌内mRNA初免/鼻内蛋白加强免疫后增强的黏膜严重急性呼吸综合征冠状病毒2免疫力
Mol Ther. 2024 Dec 4;32(12):4448-4466. doi: 10.1016/j.ymthe.2024.10.016. Epub 2024 Oct 28.
5
Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium.异源mRNA/MVA递送三聚体RBD作为针对SARS-CoV-2的有效疫苗接种方案:COVARNA联盟
Emerg Microbes Infect. 2024 Dec;13(1):2387906. doi: 10.1080/22221751.2024.2387906. Epub 2024 Aug 8.
6
SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.SARS-CoV-2 mRNA 疫苗在未感染人群和既往感染者中诱导出强烈的特异性和交叉反应性 IgG 以及不均等的中和抗体。
Cell Rep. 2022 Feb 1;38(5):110336. doi: 10.1016/j.celrep.2022.110336. Epub 2022 Jan 20.
7
A promising mRNA vaccine derived from the JN.1 spike protein confers protective immunity against multiple emerged Omicron variants.一种源自JN.1刺突蛋白的很有前景的mRNA疫苗可针对多种已出现的奥密克戎变体提供保护性免疫。
Mol Biomed. 2025 Mar 4;6(1):13. doi: 10.1186/s43556-025-00258-7.
8
Enhancing protective immunity against SARS-CoV-2 with a self-amplifying RNA lipid nanoparticle vaccine.用自扩增RNA脂质纳米颗粒疫苗增强对SARS-CoV-2的保护性免疫。
J Control Release. 2025 Feb 10;378:250-265. doi: 10.1016/j.jconrel.2024.12.003. Epub 2024 Dec 16.
9
Staggered immunization with mRNA vaccines encoding SARS-CoV-2 polymerase or spike antigens broadens the T cell epitope repertoire. stagger staggered immunization staggered mRNA vaccines encoding SARS-CoV-2 polymerase or spike antigens broadens the T cell epitope repertoire
Proc Natl Acad Sci U S A. 2024 Dec 3;121(49):e2406332121. doi: 10.1073/pnas.2406332121. Epub 2024 Nov 26.
10
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.新型冠状病毒刺突蛋白受体结合域线性表位在 COVID-19 mRNA 疫苗接种者中的高分辨率线性表位作图。
Microbiol Spectr. 2021 Dec 22;9(3):e0096521. doi: 10.1128/Spectrum.00965-21. Epub 2021 Nov 10.

引用本文的文献

1
Characterization of nuclease stability and poly(A)-binding protein binding activity of chemically modified poly(A) tail for applications.用于应用的化学修饰聚腺苷酸尾巴的核酸酶稳定性和聚腺苷酸结合蛋白结合活性的表征。
RSC Chem Biol. 2025 Aug 19. doi: 10.1039/d5cb00137d.
2
Developing Aptamer-Targeted mRNA for Immunotherapy.开发用于免疫治疗的适配体靶向mRNA。
Methods Mol Biol. 2025;2965:439-454. doi: 10.1007/978-1-0716-4742-4_22.
3
Immunogenic and Protective Properties of mRNA Vaccine Encoding Hemagglutinin of Avian Influenza A/H5N8 Virus, Delivered by Lipid Nanoparticles and Needle-Free Jet Injection.

本文引用的文献

1
Intradermal DNA vaccine delivery using vacuum-controlled, needle-free electroporation.使用真空控制的无针电穿孔进行皮内DNA疫苗递送。
Mol Ther Nucleic Acids. 2023 Oct 31;34:102070. doi: 10.1016/j.omtn.2023.102070. eCollection 2023 Dec 12.
2
Investigations into mRNA Lipid Nanoparticles Shelf-Life Stability under Nonfrozen Conditions.mRNA 脂质纳米粒非冷冻条件下货架期稳定性研究。
Mol Pharm. 2023 Dec 4;20(12):6492-6503. doi: 10.1021/acs.molpharmaceut.3c00956. Epub 2023 Nov 17.
3
Differences in SARS-CoV-2 specific humoral and cellular immune responses after contralateral and ipsilateral COVID-19 vaccination.
脂质纳米颗粒和无针喷射注射递送的编码甲型禽流感A/H5N8病毒血凝素的mRNA疫苗的免疫原性和保护特性
Vaccines (Basel). 2025 Aug 21;13(8):883. doi: 10.3390/vaccines13080883.
4
Antigen-dependent interplay of formulation, systemic innate responses, and antibody responses to multi-component replicon RNA vaccination.制剂、全身固有免疫反应和针对多组分复制子RNA疫苗接种的抗体反应之间的抗原依赖性相互作用。
Mol Ther Nucleic Acids. 2025 Jun 9;36(3):102595. doi: 10.1016/j.omtn.2025.102595. eCollection 2025 Sep 9.
5
Trans amplifying mRNA vaccine expressing consensus spike elicits broad neutralization of SARS CoV 2 variants.表达共有刺突蛋白的转录扩增mRNA疫苗引发对SARS-CoV-2变体的广泛中和作用。
NPJ Vaccines. 2025 Jun 3;10(1):110. doi: 10.1038/s41541-025-01166-1.
6
Intradermal Injection of a Protein Alone Without Additional Adjuvants Using a Needle-Free Pyro-Drive Jet Injector Induces Potent CD8 T Cell-Mediated Antitumor Immunity.使用无针热驱动喷射注射器皮内注射单独的蛋白质(不添加额外佐剂)可诱导强效的CD8 T细胞介导的抗肿瘤免疫。
Int J Mol Sci. 2025 May 7;26(9):4442. doi: 10.3390/ijms26094442.
7
Technological breakthroughs and advancements in the application of mRNA vaccines: a comprehensive exploration and future prospects.mRNA疫苗应用中的技术突破与进展:全面探索及未来展望
Front Immunol. 2025 Mar 4;16:1524317. doi: 10.3389/fimmu.2025.1524317. eCollection 2025.
8
Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy.用于癌症免疫治疗的mRNA疫苗设计中的计算生物学与人工智能
Front Cell Infect Microbiol. 2025 Jan 20;14:1501010. doi: 10.3389/fcimb.2024.1501010. eCollection 2024.
9
Jet Injection of Naked mRNA Encoding the RBD of the SARS-CoV-2 Spike Protein Induces a High Level of a Specific Immune Response in Mice.喷射注射编码严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白受体结合域(RBD)的裸露信使核糖核酸(mRNA)可在小鼠体内诱导高水平的特异性免疫反应。
Vaccines (Basel). 2025 Jan 13;13(1):65. doi: 10.3390/vaccines13010065.
10
Nano-Oncologic Vaccine for Boosting Cancer Immunotherapy: The Horizons in Cancer Treatment.用于增强癌症免疫治疗的纳米肿瘤疫苗:癌症治疗的新视野
Nanomaterials (Basel). 2025 Jan 16;15(2):122. doi: 10.3390/nano15020122.
双侧和单侧接种 COVID-19 疫苗后 SARS-CoV-2 特异性体液和细胞免疫反应的差异。
EBioMedicine. 2023 Sep;95:104743. doi: 10.1016/j.ebiom.2023.104743. Epub 2023 Aug 11.
4
A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation.一种定位纳米载体配方可使多价复制 RNA 引发多靶免疫反应,并将全身性炎症控制在有限范围内。
Mol Ther. 2023 Aug 2;31(8):2360-2375. doi: 10.1016/j.ymthe.2023.06.017. Epub 2023 Jul 3.
5
Graves' Disease after mRNA COVID-19 Vaccination, with the Presence of Autoimmune Antibodies Even One Year Later.mRNA新冠疫苗接种后发生的格雷夫斯病,甚至在一年后仍存在自身免疫抗体。
Vaccines (Basel). 2023 May 3;11(5):934. doi: 10.3390/vaccines11050934.
6
A Promising Needle-Free Pyro-Drive Jet Injector for Augmentation of Immunity by Intradermal Injection as a Physical Adjuvant.一种有前途的无针热驱动射流注射器,可通过皮内注射作为物理佐剂增强免疫。
Int J Mol Sci. 2023 May 22;24(10):9094. doi: 10.3390/ijms24109094.
7
Controllable self-replicating RNA vaccine delivered intradermally elicits predominantly cellular immunity.皮内注射的可控自我复制RNA疫苗主要引发细胞免疫。
iScience. 2023 Mar 5;26(4):106335. doi: 10.1016/j.isci.2023.106335. eCollection 2023 Apr 21.
8
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers.抗体介导的对有症状 COVID-19 的保护作用可以在低血清中和滴度下实现。
Sci Transl Med. 2023 Mar 22;15(688):eadg2783. doi: 10.1126/scitranslmed.adg2783.
9
A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines.一种新型的基于皮内纹身的注射装置可增强质粒 DNA 疫苗的免疫原性。
NPJ Vaccines. 2022 Dec 22;7(1):172. doi: 10.1038/s41541-022-00581-y.
10
An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants.一种编码严重急性呼吸综合征冠状病毒2刺突蛋白的减毒痘苗疫苗可引发广泛且持久的免疫反应,并保护食蟹猴和人血管紧张素转换酶2转基因小鼠免受严重急性呼吸综合征冠状病毒2及其变体的侵害。
Front Microbiol. 2022 Nov 18;13:967019. doi: 10.3389/fmicb.2022.967019. eCollection 2022.